tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TARA Stock Latest News

Protara Therapeutics Raises $86.3 Million in Offering
Company AnnouncementsProtara Therapeutics Raises $86.3 Million in Offering
6d ago
8K
TARA
Protara Therapeutics Completes $75 Million Stock Offering
PremiumCompany Announcements
Protara Therapeutics Completes $75 Million Stock Offering
13d ago
8K
TARA
Protara Therapeutics down 18% at $5.66 after equity offering
PremiumThe Fly
Protara Therapeutics down 18% at $5.66 after equity offering
16d ago
TARA
Protara Therapeutics 13.04M share Spot Secondary priced at $5.75
PremiumThe Fly
Protara Therapeutics 13.04M share Spot Secondary priced at $5.75
16d ago
TARA
Protara Therapeutics $75M Spot Secondary; price range $5.75-$6.25
PremiumThe Fly
Protara Therapeutics $75M Spot Secondary; price range $5.75-$6.25
17d ago
TARA
Protara Therapeutics announces $75M common stock offering
PremiumThe FlyProtara Therapeutics announces $75M common stock offering
17d ago
TARA
Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating
Premium
Ratings
Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating
18d ago
TARA
Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial
Premium
Ratings
Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial
18d ago
TARA
Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positioning
PremiumRatings
Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positioning
18d ago
TARA
Protara Therapeutics Announces Promising Phase 2 Trial Results
PremiumCompany Announcements
Protara Therapeutics Announces Promising Phase 2 Trial Results
18d ago
8K
TARA
Protara announces updated interim data from Phase 2 ADVANCED-2 trial
PremiumThe Fly
Protara announces updated interim data from Phase 2 ADVANCED-2 trial
18d ago
TARA
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC Amidst BCG Shortages
PremiumRatings
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC Amidst BCG Shortages
27d ago
TARA
Protara Therapeutics’ TARA-002: Promising Phase 2 Results Bolster Buy Rating Amidst FDA Uncertainty
PremiumRatingsProtara Therapeutics’ TARA-002: Promising Phase 2 Results Bolster Buy Rating Amidst FDA Uncertainty
1M ago
TARA
Promising Phase 2 Results and Strategic Planning Justify Buy Rating for TARA-002
Premium
Ratings
Promising Phase 2 Results and Strategic Planning Justify Buy Rating for TARA-002
1M ago
TARA
Protara Therapeutics Announces Promising Phase 2 Trial Results
Premium
Company Announcements
Protara Therapeutics Announces Promising Phase 2 Trial Results
1M ago
8K
TARA
Protara announces results from Phase 2 STARBORN-1 trial of TARA-002
PremiumThe Fly
Protara announces results from Phase 2 STARBORN-1 trial of TARA-002
1M ago
TARA
Protara Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating
PremiumRatings
Protara Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating
1M ago
TARA
Protara Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Protara Therapeutics Reports Q3 2025 Financial Results
1M ago
TARA
Protara Therapeutics: Strategic Developments and Upcoming Milestones Drive Buy Rating
PremiumRatings
Protara Therapeutics: Strategic Developments and Upcoming Milestones Drive Buy Rating
1M ago
TARA
Buy Rating for Protara Therapeutics: Promising Developments with TARA-002 in Lymphatic Malformations
PremiumRatingsBuy Rating for Protara Therapeutics: Promising Developments with TARA-002 in Lymphatic Malformations
1M ago
TARA
Protara Therapeutics: Promising Pipeline and Strong Financial Position Reinforce Buy Rating
Premium
Ratings
Protara Therapeutics: Promising Pipeline and Strong Financial Position Reinforce Buy Rating
1M ago
TARA
Protara Therapeutics reports Q3 EPS (31c), consensus (38c)
Premium
The Fly
Protara Therapeutics reports Q3 EPS (31c), consensus (38c)
1M ago
TARA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >